Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
